Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, an extensive safety database, and convenient dosing to improve the lives of patients suffering from drug-resistant seizures and neuropsychiatric disorders.



Bank of America 2016 Healthcare Conference

5/10/16 - 5/12/16 | Las Vegas, NV

BIO International Conference

6/6/16 - 6/9/16 | San Francisco, CA

Jefferies Healthcare Conference

6/7/16 - 6/10/16 | New York, NY

More Events >

Christopher M. Cashman, CEO of Marinus, discusses ganaxolone.

Clinical Trials

Physicians and patients learn more about ganaxolone and Marinus Pharmaceuticals’ clinical trials here.

View Pipeline >